Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis-Reference-Cited by-同舟云学术

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis

Published:2021-04 Issue: Volume: Page:
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Wongvibulsin Shannon,Pahalyants Vartan,Kalinich Mark,Murphy William,Yu Kun-Hsing,Wang Feicheng,Chen Steven T.,Reynolds Kerry,Kwatra Shawn G.,Semenov Yevgeniy R.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Dermatology

Reference46 articles.

1. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma;Schadendorf;J Clin Oncol,2015

2. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations;Gong;J Immunother Cancer,2018

3. CME Part II: immune checkpoint inhibitor-related dermatologic adverse events;Geisler;J Am Acad Dermatol,2020

4. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions;Hassel;Cancer Treat Rev,2017

5. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs;Haslam;JAMA Netw Open,2019

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of bullous pemphigoid and Grover disease induced by immune checkpoint therapy;Anais Brasileiros de Dermatologia;2024-09

2. Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives;Life;2024-08-25

3. Independent risk factor of drug eruption in immune checkpoint inhibitors treated liver cancer patients: high systemic immune-inflammation index;Cutaneous and Ocular Toxicology;2024-08-24

4. Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study;Cancer Letters;2024-08

5. Indurated Subcutaneous Thigh Nodules: Answer;The American Journal of Dermatopathology;2024-06